Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity

Abstract

The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least one cholinesterase inhibitor, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

Description

field of invention [0001] The present invention relates to comprising at least one with 5-HT 6 The active substance combination of a receptor-affinity compound and at least one cholinesterase inhibitor relates to a medicament comprising said active substance combination and to the use of said active substance combination in the preparation of a medicament. Background of the invention [0002] The clinical manifestation of cognitive and / or degenerative brain dysfunction is a progressive loss of memory, cognition, reasoning, judgment, and emotional stability, which progressively leads to deep mental decline and ultimately death. In one example of such a dysfunction, Alzheimer's disease is a common cause of progressive mental failure (dementia) in the elderly and is considered the fourth most common medical cause of death in the United States. Specifically, Alzheimer's disease is associated with the degeneration of basal forebrain cholinergic neurons that play an important rol...

AI Technical Summary

Problems solved by technology

[0003] Cognitive and/or degenerative brain dysfunction cannot be cured with currently used drugs, however, the symptoms of these disorders can be alleviated by the use of compounds for the treatment of cognitive disorders, in particular for the treatment of Alzheimer's disease, said Co

Images